Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5'-flanking region of the microsomal epoxide hydrolase gene (EPHX1).
The carcinogenic effects of 1,3-butadiene (BD), a mutagenic chemical widely used in the manufacture of synthetic rubber, are likely initiated through its epoxide metabolites. In humans, these epoxides are detoxified predominantly by hydrolysis, a reaction mediated by the microsomal epoxide hydrolase (mEH; EPHX1) enzyme. It appears reasonable to hypothesize that BD-exposed individuals possessing lower mEH detoxification capacity may have elevated risk of adverse health effects. The interindividual levels of mEH enzymatic activity vary considerably, and polymorphisms in the mEH gene may contribute to this variability. In addition to the well-studied coding region polymorphisms encoding Tyr113His and His139Arg substitutions, seven other polymorphic sites in the 5'-flanking region of the mEH gene have been reported. These polymorphisms appear to differentially affect mEH gene transcriptional activities. The 5'-flanking region polymorphisms exist in two linkages, the -200 linkage (-200C/T, -259C/T, -290T/G) and the -600 linkage (-362A/G, -613T/C, -699T/C), whereas the -399T/C polymorphism exists as an independent site. Because these polymorphisms may affect total mEH enzymatic activity, we hypothesized that they influence the mutagenic response associated with occupational exposure to BD. We genotyped the 5'-region of the mEH gene in 49 non-smoking workers from two styrene-butadiene rubber facilities in southeast Texas and evaluated the linkage patterns against results obtained from an autoradiographic HPRT mutant lymphocyte assay, used as a biomarker of genotoxic effect. In the study population, 67% were exposed to low BD levels, <150 parts per billion, and 33% were exposed to >150 ppb. We used the observed HPRT mutant (variant) frequency (VF) in the studied population and a 4-way first-order interaction statistical model to estimate parameters that describe the influence of exposure, genotypes and the interaction between the two on the HPRT VF in the target population. The background (baseline) VF, defined as the VF (x 10(-6)) +/- S.E.M. at low levels of BD exposure (<150 ppb) where all the genotypes under study are homozygous wild-type, was estimated to be 4.02 +/- 1.32. Exposure to >150 ppb of BD alone resulted in an estimated increase in VF of 3.42 +/- 2.47 above the baseline level. Inheritance of the variant ATT allele in the -600 linkages resulted in an estimated increase in VF of 3.39 +/- 1.67 above the baseline level. When the interaction between BD exposure and the ATT allele in the -600 linkage group was considered, a statistically significant positive interaction was observed, with an estimated increase in the VF of 10.89 +/- 2.16 (95% CI = 6.56-15.20; p = 0.0027) above baseline. These new data confirm and extend our previous findings that sensitivity to the genotoxic effects of BD is inversely correlated with predicted mEH activity.
Abdel-Rahman
Sherif Z
SZ
Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas 77555-1110, USA. sabdelra@utmb.edu
Ammenheuser
Marinel M
MM
Omiecinski
Curtis J
CJ
Wickliffe
Jeffrey K
JK
Rosenblatt
Judah I
JI
Ward
Jonathan B
JB
D024506:5' Flanking Region / Q000235:genetics*; D000328:Adult; D000368:Aged; D000483:Alleles; D002070:Butadienes / Q000009:adverse effects*; D004851:Epoxide Hydrolases / Q000235:genetics*; D008040:Genetic Linkage; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology; D008875:Middle Aged; D009153:Mutagens / Q000009:adverse effects*; D016273:Occupational Exposure / Q000009:adverse effects*; D011110:Polymorphism, Genetic
D002070:Butadienes; D005819:Genetic Markers; D009153:Mutagens; D007041:Hypoxanthine Phosphoribosyltransferase; D004851:Epoxide Hydrolases; C031763:1,3-butadiene
Res Rep Health Eff Inst. 2003 Jun;(116):1-141; discussion 143-62
12931846
Environ Mol Mutagen. 2004;44(1):65-73
15199548
Toxicology. 1996 Oct 28;113(1-3):84-90
8901886
Toxicology. 1996 Oct 28;113(1-3):91-9
8901887
Chem Biol Interact. 2001 Jun 1;135-136:465-83
11397407
Carcinogenesis. 2002 Apr;23(4):599-603
11960912
Environ Health Perspect. 1994 Nov;102 Suppl 9:79-85
7698091
Environ Mol Mutagen. 2003;42(2):106-10
12929123
Biomarkers. 2002 May-Jun;7(3):230-41
12141066
Environ Mol Mutagen. 2000;36(1):59-71
10918361
Carcinogenesis. 1998 Mar;19(3):387-93
9525271
Environ Mol Mutagen. 1991;18(2):126-35
1879404
Pharmacogenetics. 1998 Apr;8(2):157-67
10022753
Cancer Res. 1998 Dec 1;58(23):5291-3
9850050
Environ Health Perspect. 2001 Dec;109(12):1249-55
11748032
Cancer Res. 1990 Oct 15;50(20):6592-9
2208121
Mutat Res. 2004 Mar 14;558(1-2):63-74
15036120
Carcinogenesis. 1995 Oct;16(10 ):2287-93
7586124
Environ Mol Mutagen. 2003;41(2):140-6
12605384
Carcinogenesis. 2001 Mar;22(3):415-23
11238181
Mutat Res. 1998 Nov 9;419(1-3):145-54
9804932
Arch Biochem Biophys. 1994 Jun;311(2):342-9
8203896
Mutat Res. 2000 Oct;463(3):181-213
11018742
Arch Biochem Biophys. 1997 Jan 15;337(2):275-83
9016823
J Pharmacol Exp Ther. 1996 Sep;278(3):1018-27
8819481
J Biochem Toxicol. 1994 Aug;9(4):191-8
7853353
Environ Mol Mutagen. 1997;30(2):131-8
9329637
Carcinogenesis. 2000 May;21(5):965-71
10783319
Mol Pharmacol. 2005 Jan;67(1):220-30
15465926
Mutat Res. 1999 Aug 11;429(1):127-40
10434028
Toxicology. 1996 Oct 28;113(1-3):100-5
8901888
Environ Mol Mutagen. 2004;44(4):283-92
15470755
Carcinogenesis. 2000 Jan;21(1):55-62
10607734
Carcinogenesis. 2000 Dec;21(12):2219-23
11133811
Chem Biol Interact. 2001 Jun 1;135-136:387-403
11397403
Hum Mol Genet. 1994 Mar;3(3):421-8
7516776